Drugs / Hematopoietic stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07524530 | Jul 2026 → Jun 2033 expected | core binding factor acute myeloid leukemia, lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hematopoietic stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07524530 ↗ |
| Modality | Cell therapy | “Hematopoietic stem cell transplantation” NCT07524530 ↗ |
| Route | Intravenous | “The stem cell transplant will be given through the central line.” NCT07524530 ↗ |